NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd
Post# of 122
(Total Views: 151)
Posted On: 11/17/2022 4:15:50 PM
NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Featured in The Times of Israel Article
BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. The company’s CEO Amir Reichman, as an international subject matter expert on pharmaceutical manufacturing and supply chains, has been consulted by members of U.S. Congress about related topics of interest. In 2021, Reichman participated in meetings in Washington, D.C., and earlier this year BiondVax welcomed a congressional delegation to its offices and GMP biologics manufacturing facility in Jerusalem. A Times of Israel article explains details about Congress’s interest in near-shoring the U.S. medical supply chain. The publication notes that during their visit to Israel, the Congresspeople, “met with then-prime minister Naftali Bennett, opposition leader and now presumptive incoming premier Benjamin Netanyahu, Defense Minister Benny Gantz, and U.S. Ambassador Tom Nides, as well as Amir Reichman, CEO of the Jerusalem-based BiondVax Pharmaceuticals.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. The company’s CEO Amir Reichman, as an international subject matter expert on pharmaceutical manufacturing and supply chains, has been consulted by members of U.S. Congress about related topics of interest. In 2021, Reichman participated in meetings in Washington, D.C., and earlier this year BiondVax welcomed a congressional delegation to its offices and GMP biologics manufacturing facility in Jerusalem. A Times of Israel article explains details about Congress’s interest in near-shoring the U.S. medical supply chain. The publication notes that during their visit to Israel, the Congresspeople, “met with then-prime minister Naftali Bennett, opposition leader and now presumptive incoming premier Benjamin Netanyahu, Defense Minister Benny Gantz, and U.S. Ambassador Tom Nides, as well as Amir Reichman, CEO of the Jerusalem-based BiondVax Pharmaceuticals.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)